{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:29:39Z","timestamp":1793730579195,"version":"4.6.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To describe the outcomes, response patterns, and complications of intravitreal rituximab (IVR) in eyes with relapsed vitreoretinal lymphoma (VRL) despite previous treatment with ocular radiotherapy (EBRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective observational single-center study. This study included all patients diagnosed with relapsed VRL who received IVR between 2011 and 2024 at our National Ocular Oncology Service in the United Kingdom. Demographic data, systemic and ocular lymphoma history, treatment details, visual acuity, and ocular adverse events were collected from medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ten eyes of six patients with relapsed VRL were treated with IVR. All eyes had been previously treated with ocular EBRT and with whole brain radiotherapy (WBRT) (83.3%) and systemic chemotherapy (66.7%) for CNS lymphoma. Eyes with relapsed VRL were treated with a mean of four IVR injections (1 mg\/0.1 mL) per treatment course using weekly to monthly intervals. Complete ocular remission was achieved in all eyes after a single course of IVR. One eye experienced a further relapse 14 months later, successfully treated with a second course of IVR. Ocular adverse events potentially attributable to IVR included transient intraocular hypertension and mild uveitis; other complications, such as cataract, radiation retinopathy, and retinal atrophy were likely related to EBRT rather than IVR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In our cohort of relapsed VRL despite previous ocular EBRT, IVR used as a sole focal therapy was associated with high rates of ocular remission and acceptable local toxicity. These findings support the use of IVR as a standard salvage treatment in cases of relapsed VRL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_3229_25","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:00:47Z","timestamp":1779858047000},"page":"870-875","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Successful use of intravitreal rituximab as salvage therapy for relapsed vitreoretinal lymphoma"],"prefix":"10.4103","volume":"74","author":[{"given":"Irina-Elena","family":"Cristescu","sequence":"first","affiliation":[{"name":"Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Pagnacco","sequence":"additional","affiliation":[{"name":"Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhav","family":"Pershad","sequence":"additional","affiliation":[{"name":"Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umiya","family":"Harley","sequence":"additional","affiliation":[{"name":"Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hibba","family":"Quhill","sequence":"additional","affiliation":[{"name":"Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin M","family":"Salvi","sequence":"additional","affiliation":[{"name":"Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","article-title":"Primary intraocular lymphoma","volume":"59","author":"Sagoo","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3816\/CLM.2003.n.010","article-title":"Primary ocular lymphoma: Clinical features, diagnosis, and treatment","volume":"4","author":"Hormigo","year":"2003","journal-title":"Clin Lymphoma"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/11206721231211931","article-title":"A comprehensive overview of diagnosis, imaging and treatment of vitreoretinal lymphoma","volume":"34","author":"Menean","year":"2024","journal-title":"Eur J Ophthalmol"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: A diagnostic and management challenge","volume":"138","author":"Soussain","year":"2021","journal-title":"Blood"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/ceo.13668","article-title":"Intraocular chemotherapy for vitreoretinal lymphoma: A review","volume":"48","author":"Kvopka","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/bjh.17451","article-title":"Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma-20 years of experience","volume":"194","author":"Habot-Wilner","year":"2021","journal-title":"Br J Haematol"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/aol-20-27","article-title":"Primary vitreoretinal lymphoma: Recent advances and literature review","volume":"4","author":"Giuffr\u00e8","year":"2020","journal-title":"Ann Lymphoma"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10384-023-00997-6","article-title":"Diagnosis and management of vitreoretinal lymphoma: Present and future treatment perspectives","volume":"67","author":"Kaburaki","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40662-025-00434-4","article-title":"Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients (2024)","volume":"12","author":"Zhang","year":"2025","journal-title":"Eye Vis Lond Engl"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41416-021-01274-4","article-title":"Impact of COVID-19 pandemic on eye cancer care in United Kingdom","volume":"124","author":"Wang","year":"2021","journal-title":"Br J Cancer"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2011.12.097","article-title":"Risk of radiation retinopathy in patients with orbital and ocular lymphoma","volume":"84","author":"Kaushik","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/bjophthalmol-2013-304043","article-title":"Use of intravitreal rituximab for treatment of vitreoretinal lymphoma","volume":"98","author":"Larkin","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.exer.2005.09.018","article-title":"The pharmacokinetics of rituximab following an intravitreal injection","volume":"82","author":"Kim","year":"2006","journal-title":"Exp Eye Res"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/IAE.0b013e31804ac032","article-title":"Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control","volume":"27","author":"Pulido","year":"2007","journal-title":"Retina"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajoc.2018.01.032","article-title":"Intravitreal rituximab for the treatment of a secondary intraocular relapse of a large B-cell lymphoma","volume":"9","author":"Echegaray","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R17-20261103","first-page":"20","article-title":"Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin\u2019s lymphoma","volume":"42","author":"Fern\u00e1ndez Ca\u00f1abate","year":"2018","journal-title":"Farm Hosp"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s10792-021-01805-1","article-title":"Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: Initial experience from India","volume":"41","author":"Rishi","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1097-0142(19830901)52:5<878::AID-CNCR2820520523>3.0.CO;2-D","article-title":"Intraocular lymphomas. Natural history based on a clinicopathologic study of eight cases and review of the literature","volume":"52","author":"Qualman","year":"1983","journal-title":"Cancer"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/eye.2012.250","article-title":"Intraocular lymphoma: A clinical perspective","volume":"27","author":"Davis","year":"2013","journal-title":"Eye (Lond)"},{"key":"R21-20261103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/IAE.0b013e318192f574","article-title":"Rituximab for intraocular lymphoma","volume":"29","author":"Itty","year":"2009","journal-title":"Retina"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/09273948.2016.1193206","article-title":"Intraocular lymphoma: Descriptive data of 26 patients including clinico-pathologic features, vitreous findings, and treatment outcomes","volume":"26","author":"Abu Samra","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11060-014-1581-4","article-title":"Risk factors for intraocular involvement in patients with primary central nervous system lymphoma","volume":"120","author":"Cho","year":"2014","journal-title":"J Neurooncol"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40942-018-0120-4","article-title":"The diagnosis and treatment of primary vitreoretinal lymphoma: A review","volume":"4","author":"Pulido","year":"2018","journal-title":"Int J Retina Vitreous"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jamaophthalmol.2014.4755","article-title":"Treatment strategies in primary vitreoretinal lymphoma: A 17-center European collaborative study","volume":"133","author":"Riemens","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"e905","DOI":"10.1016\/j.wneu.2020.03.150","article-title":"Risk factors for early mortality in patients with primary central nervous system lymphoma: A large-cohort retrospective study","volume":"138","author":"Zhou","year":"2020","journal-title":"World Neurosurg"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.tjo.2016.05.002","article-title":"Recent progress in the diagnosis and treatment of primary vitreoretinal lymphoma","volume":"6","author":"Zhou","year":"2016","journal-title":"Taiwan J Ophthalmol"},{"key":"R28-20261103","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","article-title":"Primary vitreoretinal lymphoma: A report from an international primary central nervous system lymphoma collaborative group symposium","volume":"16","author":"Chan","year":"2011","journal-title":"Oncologist"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3229_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:01:48Z","timestamp":1793728908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3229_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3229_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"2025-12-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}